MT-TP and metabolic dysfunction-associated steatotic liver disease: We selected 17 candidate NAFLD drugs from recent drug development programs and from new targets reported in the literature, focusing on those with putative hepatic effects40,41 (Supplementary Fig. 7a and Supplementary Table 2), and screened these drugs in the FFA-induced and genetic (APOB−/− and MTTP−/−) steatosis models.